In Situ Engineered “Cascade‐Amplified” Drug‐Loaded Vesicles for Enhanced Cancer Stem Cell Therapy
Open Access
- 9 May 2026
- journal article
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 15 (5) , e70292
Abstract
Cancer stem cells (CSCs) characterized by the capacity of self‐renewal and drug resistance, are a major cause of tumour recurrence and metastasis. However, CSCs are mainly localized in the deep and hypoxic regions of the tumour microenvironment that hinder drug penetration. Furthermore, their overexpression of the CD24/Siglec10 immune checkpoint axis markedly suppresses immune clearance, severely limiting the efficacy of current therapeutic strategies. To address this challenge, this study developed an in situ engineered “cascade‐amplified” drug‐loaded vesicle delivery system, aiming to achieve deep drug delivery into CSC‐enriched regions and enhance anti‐tumour immune responses. Based on a biomimetic “core‐shell” nanoplatform (siXkr8/Dox@PMLC), this system initiates a cascade within the TME where Doxorubicin (Dox) induces tumour cells to generate drug‐loaded apoptotic bodies (ApoBDs). These ApoBDs serve as primary vesicles that, upon uptake by adjacent tumour cells, trigger secondary apoptosis, establishing a “cascade‐amplified” cycle of enhanced drug delivery. Meanwhile, the silencing of the phospholipid scramblase Xkr8 via siRNA inhibits phosphatidylserine (PS) exposure on the surface of ApoBDs, thereby preventing their recognition and clearance by M2‐type macrophages and facilitating immune phenotype remodelling. Furthermore, through targeted blockade of the CD24/Siglec‐10 immune axis, the nanoplatform enhances macrophage‐mediated phagocytosis of CSCs. In summary, this strategy achieves deep eradication of CSCs and synergistically enhances anti‐tumour immunotherapy, demonstrating significant translational potential.Keywords
Funding Information
- National Natural Science Foundation of China (82572400 82573314 82273478 32201156)
- Natural Science Foundation of Henan Province (242300421196)
This publication has 43 references indexed in Scilit:
- TPP1 Delivery to Lysosomes with Extracellular Vesicles and their Enhanced Brain Distribution in the Animal Model of Batten DiseaseAdvanced Healthcare Materials, 2019
- Efferocytosis Fuels Requirements of Fatty Acid Oxidation and the Electron Transport Chain to Polarize Macrophages for Tissue RepairCell Metabolism, 2019
- Exposure of phosphatidylserine on the cell surfaceCell Death & Differentiation, 2016
- Expression of CD24, a Stem Cell Marker, in Pancreatic and Small Intestinal Neuroendocrine Tumors.American Journal of Clinical Pathology, 2015
- Biological properties of extracellular vesicles and their physiological functionsJournal of Extracellular Vesicles, 2015
- Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-deliveryBiomaterials, 2013
- A subpopulation of CD24+ cells in colon cancer cell lines possess stem cell characteristicsNeoplasma, 2012
- Cancer stem cells at the crossroads of current cancer therapy failures—Radiation oncology perspectiveSeminars in Cancer Biology, 2010
- Drug penetration in solid tumoursNature Reviews Cancer, 2006
- The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid TumorsClinical Cancer Research, 2005